How does Vyndamax compare with its new competitors?
BridgeBio's Attruby (approved Nov 2024) achieves near-complete stabilisation and showed 34% lower worsening risk vs tafamidis in real-world data; Alnylam's Amvuttra (approved Mar 2025) silences TTR production at $476,000/year. A July 2026 trial failure for a rival silencer reinforced stabilisers as frontline treatment.
Vyndamax now competes with BridgeBio's Attruby (acoramidis), approved on November 22, 2024, and Alnylam's Amvuttra (vutrisiran), approved for ATTR-CM in March 2025. Attruby is also a stabiliser; BridgeBio priced it at about $244,000 a year, below tafamidis. Attruby it is the only drug ATTR-CM drug that achieves "near-complete stabilization". A real-world study of 618 new patients found a 34% lower risk of clinical worsening with acoramidis than tafamidis over about 4.6 months. Amvuttra is a "silencer" that reduces TTR production, priced at about $476,000 a year. A second silencer, AstraZeneca and Ionis's Wainua (eplontersen), failed its ATTR-CM outcomes trial in July 2026. Most participants were already on a stabiliser, and Wainua showed no added benefit on top of stabiliser therapy. Analysts said the result "benefits stabilizers" and reinforces them as frontline treatment.